https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/TAGRISSO-osimertinib-demonstrated-strong-overall-survival-benefit-in-the-ADAURA-Phase-III-trial-43201887/?utm_source=telegram&utm_medium=social&utm_campaign=share